Slide background
Slide background




Five cobalt salts proposed for restriction - ECHA

ID 7847 | | Visite: 1493 | News ChemicalsPermalink: https://www.certifico.com/id/7847

Temi: Chemicals , Reach

Sali di cobalto proposti per la restrizione

Five cobalt salts proposed for restriction

Update 21.02.2019

In response to a request by the European Commission, ECHA submitted a restriction dossier in October 2018 concerning five cobalt salts. We take a closer look at the proposed restriction.

How are cobalt salts used?

The five cobalt salts cobalt sulphatecobalt dichloridecobalt dinitratecobalt carbonate and cobalt di(acetate) are produced and widely used to manufacture chemicals, catalysts, batteries, feed grade materials and biogas. The salts are also used for surface treatments and in fermentation processes.

Around 30 000 tonnes of the salts are used each year in the EU. They are used in the largest amounts as transported isolated intermediates to manufacture other chemicals. These would still be subject to the proposed restriction.

Over the last decade, the volumes placed on the EU market have doubled, and the rise in demand is likely to continue, as there is expected to be an increased need for rechargeable batteries, biotechnology and health applications.

It is estimated that around 35 000 workers are exposed to the cobalt salts at around 20 000 industrial sites within the EU.

Why are the cobalt salts a concern?

Each of the five cobalt salts is classified as a carcinogen and reproductive toxicant (category 1B) and as a skin and respiratory sensitiser under the CLP Regulation. ECHA identified them as substances of very high concern and added them to the Candidate List for authorisation back in 2010.

In 2016, ECHA’s Committee for Risk Assessment (RAC) agreed that they should be considered as genotoxic carcinogens for which no safe level of exposure exists. Therefore, RAC endorsed a dose-response relationship deriving a value above which humans should not be exposed in case of occupational exposure. Exceeding this value could result in a higher lifetime cancer risk.

ECHA’s examination also showed that the individual excess lifetime cancer risk levels could be higher in several industrial sectors and be related to various activities involving uses of the cobalt salts in solid forms such as powders and granules, and activities such as electroplating, where the use of electrical currents may give rise to aerosols.

What’s being proposed?

ECHA has found that the risks arising from the manufacture and use of the cobalt salts are not adequately controlled, and suggests that this needs to be addressed at the Union level. This goes against the conclusions of the registrants’ chemical safety reports, where it is assumed that the salts are threshold substances and that the uses are safe.

As the most appropriate measure to address the identified risks, ECHA proposes to implement a reference exposure value. Registrants should use this in their chemical safety assessments to determine suitable operational conditions and risk management measures for their uses of the cobalt salts. The value should also be communicated to all actors in the supply chain through extended safety data sheets.

Under the proposed restriction, manufacturers and downstream users will have to show that they are compliant with the reference value that has been set. The proposal gives flexibility to industry in identifying and implementing adequate measures to control the risks, but they will have to monitor how effective the measures are in reducing risk to the required level.

The proposal assesses the following reference values:

- 10 µg Co/m3;
- 1 µg Co/m3;
- 0.1 µg Co/m3; and
- 0.01 µg Co/m3.

For each of these, the individual excess lifetime cancer risk varies from 1/100 to 1/10 000, resulting in different figures for workers affected and annual costs. The overall aim is to decrease the excess cancer risk levels and the number of cancer cases arising from occupational exposure to the cobalt salts through inhalation.

Industry response to the restriction

Based on responses received from the cobalt industry during the preparation of the dossier, there are no suitable alternatives available for the current uses of the five cobalt salts.

However, taking into account differences in reference exposure values and in risk management measures by industry, the available information does not indicate that production sites would have to close down due to the proposed restriction.

In the proposal, ECHA considers that some companies may have to move to using liquid forms of cobalt salts, instead of solid forms. However, the Agency expects that industry will not implement such a switch unless the proposed restriction is put in place.

Next steps

In December 2018, the dossier passed a conformity check and is now being assessed by ECHA’s scientific committees. The final opinion is expected at the end of 2019.

Cobalt saltsECCAS
Cobalt sulphate 233-334-2 10124-43-3; 10026-24-1
Cobalt dinitrate 233-402-1 10141-05-6; 10026-22-9
Cobalt dichloride 231-589-4 7646-79-9; 7791-13-1
Cobalt carbonate 208-169-4 513-79-1
Cobalt di(acetate) 200-755-8 71-48-7; 6147-53-1

 

 

 

 

 

Collegati

Pin It
Scarica questo file (Commission's request to ECHA 12 April 2017.pdf)Commission\'s request to ECHA 12 April 2017ECHA 2017IT196 kB(207 Downloads)

Tags: Chemicals Reach

Ultimi archiviati Chemicals

Dossier immissione in commercio PMC disinfettante
Mag 27, 2020 57

Dossier immissione in commercio PMC disinfettante

Dossier immissione in commercio PMC disinfettante Schema per la presentazione del dossier ai fini dell’autorizzazione all’immissione in commercio di un presidio medico chirurgico (PMC) disinfettante (per le mani e per le superfici) Ministero della Salute, 15.04.2020 Il presente documento definisce… Leggi tutto
Mag 27, 2020 26

Decreto 11 marzo 2014

Decreto 11 marzo 2014 Disposizioni riguardanti i presidi medico chirurgici contenenti principi attivi biocidi a seguito dell'emanazione dei regolamenti di esecuzione di cui all'articolo 9 del Regolamento (UE) n. 528/2012. (GU n.77 del 02-04-2014)______ IL DIRETTORE GENERALE dei dispositivi medici,… Leggi tutto
Mag 26, 2020 97

Regolamento di esecuzione (UE) 2015/1730

Regolamento di esecuzione (UE) 2015/1730 Regolamento di esecuzione (UE) 2015/1730 della Commissione, del 28 settembre 2015, che approva il perossido di idrogeno come principio attivo esistente destinato a essere utilizzato nei biocidi dei tipi di prodotto 1, 2, 3, 4, 5 e 6. GU L 252, 29.9.2015… Leggi tutto
Mag 25, 2020 72

Provvedimento 5 febbraio 1999

Provvedimento 5 febbraio 1999 Approvazione dei requisiti della domanda e relativa documentazione da presentare ai fini dell'autorizzazione all'immissione in commercio ed alla variazione di autorizzazioni gia' concesse per i presidi medicochirurgici. (GU Serie Generale n.34 del 11-02-1999) IL… Leggi tutto
Indicazioni ad interim sanificazione ambienti interni contesto sanitario
Mag 22, 2020 194

Indicazioni ad interim sanificazione ambienti interni contesto sanitario

Indicazioni ad interim sanificazione ambienti interni contesto sanitario Rapporto ISS COVID-19 n. 20/2020 Rev. 14 maggio 2020 Indicazioni ad interim per la sanificazione degli ambienti interni nel contesto sanitario e assistenziale per prevenire la trasmissione di SARS-CoV 2 Questo documento… Leggi tutto

Più letti Chemicals

Regolamento  CE  n  178 2002
Feb 28, 2020 29510

Regolamento (CE) N. 178/2002

Regolamento (CE) n. 178/2002 Regolamento (CE) n. 178/2002 del Parlamento europeo e del Consiglio del 28 gennaio 2002 che stabilisce i principi e i requisiti generali della legislazione alimentare, istituisce l'Autorità europea per la sicurezza alimentare e fissa procedure nel campo della sicurezza… Leggi tutto